PMID- 23390386
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130318
LR  - 20220316
IS  - 1554-169X (Print)
IS  - 1554-169X (Linking)
VI  - 1
IP  - 3
DP  - 2004 Jul
TI  - Targeted IgE Therapy for Patients With Moderate to Severe Asthma.
PG  - 56-61
AB  - It is well established that the proinflammatory cytokine immunoglobulin E (IgE) 
      is a primary contributor to development of allergic airway inflammation following 
      allergen exposure. Recent data suggest that blocking the effects of IgE with 
      omalizumab, a recombinant DNA-derived humanized monoclonal antibody that inhibits 
      the binding of IgE, is an effective strategy for the treatment of asthma, 
      particularly for moderate to severe asthma that is difficult to control with 
      inhaled corticosteroids and traditional controller medications. Targeting 
      specific steps in the inflammatory cascade with omalizumab improves daytime and 
      nocturnal symptom control, reduces exacerbations, and decreases the need for 
      inhaled corticosteroids and beta(2) agonists. These benefits, along with improved 
      daily functioning, have resulted in a clinically meaningful improvement in 
      asthma-related quality of life for a substantial number of patients. This paper 
      briefly reviews the contribution of IgE to the development of airway 
      inflammation, discusses the clinical benefits of IgE-blocker therapy, and 
      profiles the patient who stands to benefit from this new and innovative form of 
      therapy.
FAU - Chipps, Bradley E
AU  - Chipps BE
AD  - Medical Director, Capital Allergy and Respiratory Disease Center, Sacramento, 
      Calif.
FAU - Marshik, Patricia L
AU  - Marshik PL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biotechnol Healthc
JT  - Biotechnology healthcare
JID - 101241418
PMC - PMC3564312
EDAT- 2004/07/01 00:00
MHDA- 2004/07/01 00:01
PMCR- 2004/07/01
CRDT- 2013/02/08 06:00
PHST- 2013/02/08 06:00 [entrez]
PHST- 2004/07/01 00:00 [pubmed]
PHST- 2004/07/01 00:01 [medline]
PHST- 2004/07/01 00:00 [pmc-release]
AID - bh0103056 [pii]
PST - ppublish
SO  - Biotechnol Healthc. 2004 Jul;1(3):56-61.